North American institutional cannabis investors now see the European medical market as a crucial driver of growth, a new survey suggests.
ATB Cormark Capital Markets’ latest ‘Capital Markets Cannabis Investor Sentiment Survey’ found that nearly half (47.1%) of US-focused respondents believe multi-state operators (MSOs) should participate in international medical cannabis markets, up from 37.5% in Spring 2026, with the share saying MSOs should not participate collapsing from 37.5% to 11.8%.
Similarly, a third of Canada-focused respondents now rank continued international growth as a top-two factor that would increase their willingness to allocate capital to Canadian licensed producers, a sharp jump from 7.1% in spring 2026 and the biggest single shift in the Canadian half of the survey since it began in 2023. Investor sentiment on international cannabis markets more broadly has also firmed, with 44.4% stating they were more bullish than six months earlier.
M&A, meanwhile, has re-emerged as a top capital-allocation priority among US-focused respondents, cited in the top two preferences by 56.3%, up from 24% in Spring 2026 and now tied with balance-sheet deleveraging as the leading option.
Green Thumb Industries topped the US consensus-long rankings at 50%, followed by Trulieve at 21.4%. In Canada, Village Farms and Cronos led the consensus-long list, with Canopy Growth named the consensus underweight.
This shift in sentiment is already playing out across the global cannabis market, as transatlantic M&A deals continue to be signed. As Business of Cannabis reported in August, even Curaleaf’s ongoing efforts to acquire Canada’s Aurora are a battle for European presence.
Aurora, Tilray, Oranigram, Curaleaf and now Canadian-listed Red White & Bloom’s have all moved to expand their European footprints this year. Last week Red White & Bloom’s European platform HEAL Group announced the acquisition of a majority stake in Germany’s Grünhorn Group, alongside a 61.3% combined stake in UK telemedicine groups Zerenia and Leva.
Despite both of these factors, broad deployment of capital is yet to materialise. ATB’s survey, fielded between September 21 and September 29 and covering 17 institutional cannabis investors, found that only 29.4% of US-focused respondents had actually increased net exposure to the sector over the last six months, with 64.7% reporting no change.
Frederico Gomes, CFA, Equity Research Analyst at ATB Cormark Capital Markets, told Business of Cannabis: “We see two primary reasons why bullish sentiment has not yet meaningfully translated into capital flows.
READ MORE…
“The sector has a long history of false starts and policy delays. Therefore, even when investors feel optimistic about near-term catalysts like rescheduling, past experience keeps them in a wait-and-see mode until regulatory reforms actually materialise.”
Respondents assigned a 65% probability to full rescheduling to Schedule III within six months, while 70.6% expected rescheduling to be done ahead of the US midterm elections.
They also gave a 67% probability to broader sector up-listings to NASDAQ or NYSE, marking the first time in the survey’s history that the up-listing read has crossed the 50% threshold.
Despite the proximity of these regulatory advancements, Gomes pointed to the remaining roadblocks still in place for investors.
“Adult-use cannabis remains federally illegal, creating compliance, custody, and mandate restrictions for many institutional funds. Furthermore, because most US operators trade on second-tier exchanges with limited trading liquidity, broad institutional capital cannot easily enter the space.
“Major catalysts such as rescheduling and the federal intoxicating hemp ban, while widely expected, are far from fully priced in, offering significant upside for unconstrained investors that can build their positions ahead of these events.”
The next sector catalyst flagged in the report is the October 13 DEA response deadline on the inclusion of the GAO report in the rescheduling process.









